Susquehanna Fundamental Investments’s Madrigal Pharmaceuticals MDGL Stock Holding History

Susquehanna Fundamental Investments’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,186	Closed	-$584K	–	979
2024 Q1	$584K	Buy	+2,186	New	+$515K	0.03%	442
2023 Q1	–	Sell	-2,507	Closed	-$728K	–	1046
2022 Q4	$728K	Buy	+2,507	New	+$245K	0.01%	751
2022 Q1	$685K	Sell	6,985 -3,618	-34%	-$305K	0.01%	974
2021 Q4	$898K	Buy	10,603 +1,962	+23%	+$161K	0.02%	697
2021 Q3	$689K	Buy	+8,641	New	+$746K	0.01%	1054
2021 Q2	–	Sell	-2,068	Closed	-$242K	–	1720
2021 Q1	$242K	Buy	+2,068	New	+$241K	﹤0.01%	1351

Other funds holding MDGL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna Fundamental Investments's MDGL Position: Q2 2024 in Review

Susquehanna Fundamental Investments sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2024, closing a stake of 2,186 shares — an estimated $584K sold.

Susquehanna Fundamental Investments first reported a position in MDGL in Q1 2021 and held it in 6 quarters. The position peaked at $898K in Q4 2021. 257 funds tracked by Wall St. Rank hold MDGL as of Q2 2024.

Susquehanna Fundamental Investments reported no remaining Madrigal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Susquehanna Fundamental Investments sold 2,186 Madrigal Pharmaceuticals shares in Q2 2024, an estimated $584K.
Susquehanna Fundamental Investments first reported a position in Madrigal Pharmaceuticals in Q1 2021 and held it in 6 quarters.
Susquehanna Fundamental Investments's Madrigal Pharmaceuticals position peaked at $898K in Q4 2021.
257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2024.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2024, filed 15 Aug 2024.